13 May 2020 Under a non-exclusive agreement, Gilead has granted rights to JLS to register, manufacture, and sell the investigational drug Remedisvir in 127 countries (nearly all low-income/lower middle-income as well as several upper-middle/high-income nations), including India. This implies that currently 10 vials (1 of 200mg and 9 of 100mg) are required per patient (under critical condition). However, the top-10 countries (that form 84% of severely critical patients) are not a part of the 127 countries list for which JLS has supply permission, implying limited opportunity over the near term. We are awaiting the outcome of a study related to the use of Remedisvir for mild COVID- 19 positive patients, which can be a significant opportunity in the offing. In addition to JLS, Gilead has similar non-exclusive agreements with Cipla, Hetero, Ferozsons and Mylan to manufacture and sell Remedisvir in 127 countries.